⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693128 | 0.90 | MME (0.31) | — | |
| SCHEMBL15859416 | 0.90 | — | — | |
| SCHEMBL3093430 | 0.88 | CYP2C19 (0.31) | — | |
| SCHEMBL19744800 | 0.84 | — | — | |
| SCHEMBL2746734 | 0.84 | LMNA (0.30) | — | |
| SCHEMBL22363136 | 0.81 | — | — | |
| SCHEMBL16653661 | 0.78 | — | — | |
| SCHEMBL20514390 | 0.77 | — | — | |
| SCHEMBL22363082 | 0.77 | — | — | |
| SCHEMBL22363079 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999713-B2 | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2024-06-04 | — | — | US | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240132465-A1 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20240109891-A1 | NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| US-11820734-B2 | Cathepsin inhibitors | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2023-11-21 | — | — | US | disclosed |
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2023049886-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022258052-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20220227705-A1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2022-07-21 | — | — | US | disclosed |
| US-7132457-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-6881754-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-19 | — | — | US | disclosed |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA AB | 2005-03-03 | — | — | US | disclosed |
| EP-1242364-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352897-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |